SCHEMBL897035

SCHEMBL897035

CC(C)CC(C)n1c(=O)[nH]c2nc[nH]c2c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 10/20 0.55
ADORA2A P29274 6/20 0.55
PDE4A P27815 4/20 0.55
PDE4B Q07343 4/20 0.55
PDE4C Q08493 4/20 0.55
PDE4D Q08499 4/20 0.55
ADORA3 P0DMS8 6/20 0.52
ADORA1 P30542 2/20 0.38
ACHE P22303 1/20 0.38
GDA Q9Y2T3 1/20 0.38
CFTR P13569 2/20 0.38
PDE2A O00408 2/20 0.38
PDE1A P54750 2/20 0.38
PDE1B Q01064 2/20 0.38
PDE1C Q14123 2/20 0.38
PDE5A O76074 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917584 0.89 ADORA2B (0.55) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL12413533 0.83 ADORA2B (0.63) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL150602 0.81 ADORA2B (0.59) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL10535015 0.79 ADORA2A (0.57) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL60158 0.77 ADORA2A (0.70) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL7035609 0.75 ADORA2B (0.52) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL59949 0.74 ADORA2B (0.72) ADORA2BADORA2APDE4APDE4BPDE4C
1-Methylxanthine SCHEMBL27663813 0.74 ADORA2B (0.77) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL941656 0.74 ADORA2B (0.55) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL7801074 0.72 ADORA2B (0.56) ADORA2BADORA2APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109783-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE MESOBLAST, INC. (US) 2026-04-23 US disclosed
US-12275801-B2 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase MESOBLAST, INC. (US) 2025-04-15 US disclosed
US-20240101961-A1 Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof MESOBLAST, INC. (US) 2024-03-28 US disclosed
US-20210355447-A1 Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof MESOBLAST, INC. (US) 2021-11-18 US disclosed
US-20200332023-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE MESOBLAST, INC. (US) 2020-10-22 US disclosed
US-10609922-B2 Protection of progenitor cells and regulation of their differentiation PROTEOBIOACTIVES PTY LTD (AU) 2020-04-07 US disclosed
EP-2380971-B1 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS MESOBLAST INC (US) 2020-02-12 EP disclosed
US-10544394-B2 Method of increasing proliferation of bone marrow mononuclear cells expressing STRO1-dim MESOBLAST, INC. (US) 2020-01-28 US disclosed
US-10421946-B2 Perivascular mesenchymal precursor cells MESOBLAST, INC. (US) 2019-09-24 US disclosed
US-20190201444-A1 GLYCOENGINEERING OF E-SELECTIN LIGANDS SACKSTEIN ROBERT (US) 2019-07-04 US disclosed
WO-2006108229-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE ANGIOBLAST SYSTEMS, INC. (US) 2006-10-19 WO disclosed
US-20060193840-A1 Perivascular mesenchymal precursor cell induced blood vessel formation MESOBLAST INTERNATIONAL SÀRL (CH) 2006-08-31 US disclosed
WO-2006032075-A1 METHOD OF ENHANCING PROLIFERATION AND/OR SURVIVAL OF MESENCHYMAL PRECURSOR CELLS (MPC) ANGIOBLAST SYSTEMS, INC. (US) 2006-03-30 WO disclosed
WO-2006032092-A1 MULTIPOTENTIAL EXPANDED MESENCHYMAL PRECURSOR CELL PROGENY (MEMP) AND USES THEREOF ANGIOBLAST SYSTEMS, INC. (US) 2006-03-30 WO disclosed
EP-1613741-A1 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS Angioblast Systems Incorporated (US) 2006-01-11 EP disclosed
EP-1613335-A1 PERIVASCULAR MESENCHYMAL PRECURSOR CELL INDUCED BLOOD VESSEL FORMATION Angioblast Systems Incorporated (US) 2006-01-11 EP disclosed
US-20050158289-A1 Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals ANGIOBLAST SYSTEMS, INCORPORATED 2005-07-21 US disclosed
US-20050019911-A1 Mesenchymal precursor cell MEDVET SCIENCE PTY LTD (AU) 2005-01-27 US disclosed
WO-2004084921-A1 PERIVASCULAR MESENCHYMAL PRECURSOR CELL INDUCED BLOOD VESSEL FORMATION ANGIOBLAST SYSTEMS INCORPORATED (US) 2004-10-07 WO disclosed
WO-2004085630-A1 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS ANGIOBLAST SYSTEMS INCORPORATED (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10609922-B2 Protection of progenitor cells and regulation of their differentiation CD44, MCL1, NES ADORA2B 4107/4885ADORA2A 3677/4885PDE4A 4216/4885
US-20260109783-A1 ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE ALPP, S100P, ALPG ADORA2B 4465/4885ADORA2A 4578/4885PDE4A 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.